We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $152.43, marking a -0.54% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.56%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw a decrease of 0.51%.
The world's biggest maker of health care products's stock has dropped by 1.71% in the past month, exceeding the Medical sector's loss of 2.25% and lagging the S&P 500's gain of 7.37%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company is predicted to post an EPS of $2.65, indicating a 6.03% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $22.77 billion, indicating a 1.42% upward movement from the same quarter last year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $10.60 per share and revenue of $91.19 billion. These results would represent year-over-year changes of +6.21% and +2.66%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Johnson & Johnson is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Johnson & Johnson is presently being traded at a Forward P/E ratio of 14.45. This indicates a premium in contrast to its industry's Forward P/E of 13.26.
Also, we should mention that JNJ has a PEG ratio of 2.32. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.23.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 41, finds itself in the top 17% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ - Free Report) closed at $152.43, marking a -0.54% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.56%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw a decrease of 0.51%.
The world's biggest maker of health care products's stock has dropped by 1.71% in the past month, exceeding the Medical sector's loss of 2.25% and lagging the S&P 500's gain of 7.37%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company is predicted to post an EPS of $2.65, indicating a 6.03% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $22.77 billion, indicating a 1.42% upward movement from the same quarter last year.
JNJ's full-year Zacks Consensus Estimates are calling for earnings of $10.60 per share and revenue of $91.19 billion. These results would represent year-over-year changes of +6.21% and +2.66%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Johnson & Johnson. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Johnson & Johnson is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Johnson & Johnson is presently being traded at a Forward P/E ratio of 14.45. This indicates a premium in contrast to its industry's Forward P/E of 13.26.
Also, we should mention that JNJ has a PEG ratio of 2.32. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.23.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 41, finds itself in the top 17% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.